XOMA Awarded Key Flexible Manufacturing Patent
November 20 2013 - 9:00AM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of therapeutic antibodies, today announced that the
United States Patent and Trademark Office has awarded it U.S.
patent no. 8,584,349, entitled "Flexible Manufacturing System."
This patent relates to modular, flexible manufacturing facilities.
"This is a fundamental patent for XOMA in the fast emerging
flexible manufacturing field," stated Pat Scannon, Founder and
Chief Scientific Officer of XOMA. "With 5 of the top 10
selling drugs globally being biologics, the emphasis on discovering
and developing new biologic drug candidates has never been
higher. Fast, flexible manufacturing techniques address a key
hurdle in early stage biologics development – that of creating drug
supply in appropriate quantities in the clinical development
process."
The patent is directed to a flexible system of movable
manufacturing bays, adapted to easily and quickly connect to a
central supply of utilities such as air, water, and electricity.
This unique arrangement facilitates flexible design and eliminates
change-over downtime, which translates into significantly reduced
capital expenditures, production costs, and maintenance costs. The
flexible manufacturing system can be applied to fields as diverse
as pharmaceuticals, biologics, and electronics.
About XOMA
XOMA's portfolio of innovative product candidates is the result
of the Company's focus on allosteric modulation, which offers
opportunities to develop new classes of therapeutic antibodies with
the potential to treat a wide range of human diseases. XOMA is
developing its lead product gevokizumab (IL-1 beta modulating
antibody) with SERVIER through a global Phase 3 program in
non-infectious uveitis and ongoing proof-of-concept studies in
other IL-1-mediated diseases. XOMA's scientific research also
produced the XMet program, which consists of three classes of
preclinical antibodies, including Selective Insulin Receptor
Modulators (SIRMs) that could have a major effect on the treatment
of diabetes.
More detailed information can be found at www.xoma.com.
Forward-Looking Statements
Certain statements contained in this press release including,
but not limited to, statements related to anticipated timing of
initiation and completion of clinical trials and proof-of-concept
trials, anticipated size of clinical trials, continued sales of
approved products, sufficiency of our cash resources and
anticipated levels of cash utilization, or that otherwise relate to
future periods are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These statements are based on
assumptions that may not prove accurate, and actual results could
differ materially from those anticipated due to certain risks
inherent in the biotechnology industry and for companies engaged in
the development of new products in a regulated
market. Potential risks to XOMA meeting these
expectations are described in more detail in XOMA's most
recent filing on Form 10-K and in other SEC
filings. Consider such risks carefully when
considering XOMA's prospects. Any forward-looking
statement in this press release represents XOMA's views only
as of the date of this press release and should not be relied upon
as representing its views as of any subsequent
date. XOMA disclaims any obligation to update any
forward-looking statement, except as required by applicable
law.
CONTACT: XOMA Corporation
Company and Investor Contact:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
Media Contact:
Canale Communications
Carolyn Hawley
619-849-5375
carolyn@canalecomm.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024